Drugs / BVRS-GamVac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04130594 | Nov 2019 → Jul 2021 | Middle East respiratory syndrome | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BVRS-GamVac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04130594 ↗ |
| Modality | Vaccine | “adenoviral-based vaccine against MERS - BVRS-GamVac.” NCT04130594 ↗ |
| Route | Intramuscular | “a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration” NCT04130594 ↗ |